Abstract Background This study aims to evaluate the clinical effectiveness and feasibility of a novel bilateral sequential accelerated theta-burst stimulation (BS-aTBS) protocol in treatment-resistant depression (TRD) patients, compared to a standard intermittent TBS (a-iTBS) protocol. Methods In this randomized controlled clinical trial, 94 TRD patients were randomly assigned to receive either BS-aTBS ( n = 46) or a-iTBS ( n = 48). Both groups delivered 10 daily TBS sessions (1800 pulses/session) for 5 consecutive days. The primary outcome was score on the 24-item Hamilton Depression Rating Scale (HDRS-24) after treatment, normalized to baseline (week 0). Results Both BS-aTBS and a-iTBS protocols significantly reduced HDRS-24 scores by week 1 (65.52% vs. 54.32%, p = 0.008) and week 5 (77.10% vs. 67.77%, p = 0.006), and the BS-aTBS group showed significantly greater symptom improvement at both time points. Compared to a-iTBS, the BS-aTBS yielded higher response rates at week 1 (78.26% vs. 58.33%, p = 0.038) and week 5 (93.48% vs. 77.08%, p = 0.026), and elicited greater alleviation for anxiety and suicidal ideation at week 5. Moreover, clinical improvement on sleep quality and cognitive abilities was larger in the BS-aTBS group, and the effects on anhedonia and alexithymia were comparable between the two protocols. No serious adverse events were observed. Conclusions The BS-aTBS protocol provided rapid and well-tolerated antidepressant effects in TRD patients lasting for 1 month, with additional benefits for anxiety and suicidal ideation. Considering its clinical advantages and shortened treatment time, the BS-aTBS may serve as a promising treatment protocol for TRD patients with high feasibility and efficiency. Trial registration This trial was registered at Chinese Clinical Trial Registry (ChiCTR2400091459).
Li et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: